Enhanced Games Goes Public On NYSE At $1.2 Billion Valuation With Notable Investors

Enhanced Games (@Enhanced_Games) became one of the most unconventional entrants in sports and capital markets, going public on the NYSE under the ticker $ENHA ahead of hosting its first competition and promoting an Olympic-style format where performance-enhancing drugs are permitted under medical supervision. The SPAC-backed listing closed at roughly a $1.2B enterprise value, positioning the company as both a sports platform and biotech bet on “human enhancement,” with events planned across swimming, track & field, and weightlifting featuring cash prizes for record-breaking performances. Founded by Christian Angermayer and Maximilian B. Martin, the New York City–based company has drawn a high-profile investor base including Donald Trump Jr., Christian Angermayer, Balaji Srinivasan, and Cameron and Tyler Winklevoss, while framing itself as a pro-science alternative to traditional anti-doping sports governance amid ongoing criticism over safety and normalization concerns. This content is a paid advertisement and is provided for informational and marketing purposes only. This is not financial advice. Viewers should conduct their own research and consult a qualified financial advisor before making investment decisions. FOUNDERS: Christian Angermayer (@ChristianAngermayer), Maximilian B. Martin (@MaximilianBMartin) INVESTORS: Donald Trump Jr (@DonaldJTrumpJR), Balaji Srinivasan (@BalajiS),, Cameron Winklevoss (@Winklevoss), Tyler Winklevoss (@TylerWinklevoss) VALUATION: $1,200,000,000 HQ: New York City #VentureCapital #EnhancedGamesPartner #ChristianAngermayer #MaximilianBMartin #TradedVC

More Deals

View All

Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts. FOUNDERS: Ben Lamm & George Church TARGET VALUATION: $23,000,000,000 HQ: Dallas, Texas #VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC